IMGN151-1001: A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (anti-FRa antibody-drug conjugate) in Adult Patients with Recurrent Endometrial Cancer and Recurrent, High-Grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers

We are doing this study to test the safety and effectiveness of the test drug. The purpose of the study is to answer the following questions: What are the side effects of the test drug? At what dose levels are the side effects seen? What is the highest dose that can be given to patients without causing severe side effects? How long does the test drug stay in your blood? Can the test drug cause your cancer to shrink, remain stable, or grow more slowly?